84449-80-9

Basic information

• Product Name: 4-[2-(1-Pipiridine)ethoxybenzoic acid hydrochloride
• Synonyms: 4-(2-Piperdinoethoxy)-benzoic acid Hydrochloride;4-[2-(1-Pipiridine)e;4-{2-(1-Piperidino)ethoxy}benzoic acid HCl;Benzoic acid,4-[2-(1-piperidinyl)ethoxy]-, hydrochloride (1:1);Raloxifene Benzoic Acid Impurity;4-[2-(1-piperridiyl)ethoxy] benzoic acid hydro chloride;4-(2-PIPERIDIN-1-YL-ETHOXY)-BENZOIC ACID HYDROCHLORIDE;4-(2-PIPERIDINOETHOXY)BENZOIC ACID HCL
• CAS NO: 84449-80-9
• Molecular Formula: C₁₄H₁₉NO₃*ClH
• Molecular Weight: 285.77
• EINECS: 282-882-9
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 84449-80-9.mol

Chemical Properties

• Melting Point: 267-271°C dec.
• Boiling Point: 413.2 °C at 760 mmHg
• Flash Point: 203.7 °C
• Appearance: /
• Vapor Pressure: 4.9E-08mmHg at 25°C
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: 4-[2-(1-Pipiridine)ethoxybenzoic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(1-Pipiridine)ethoxybenzoic acid hydrochloride(84449-80-9)
• EPA Substance Registry System: 4-[2-(1-Pipiridine)ethoxybenzoic acid hydrochloride(84449-80-9)

Safety Data

• Hazardous Substances Data: 84449-80-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H17NO3.ClH/c15-13(16)11-3-5-12(6-4-11)17-10-9-14-7-1-2-8-14;/h3-6H,1-2,7-10H2,(H,15,16);1H

Upstream product

• 93148-78-8 ethyl 4-(2-Piperidinylethoxy)benzoate 
• 2008-75-5 N-chloroethylpiperidine hydrochloride 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 408538-22-7 N-hydroxyethylpiperidine 
• 628-63-7 1-pentyl acetate 
• 98-59-9 p-toluenesulfonyl chloride 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 1648-99-3 2,2,2-Trifluoroethanesulfonyl chloride 
• 89407-97-6 4-[2-(N-piperidine)-ethoxy]benzoic acid methyl ester 

Downstream Products

• 933824-13-6 C₃₃H₃₄N₂O₃ 
• 933824-16-9 C₃₅H₃₈N₂O₃ 
• 933824-15-8 C₃₃H₃₂N₄O₇ 
• 933824-14-7 C₃₃H₃₂Cl₂N₂O₃ 
• 82640-04-8 raloxifene hydrochloride 
• 84449-84-3 6-benzenesulfonyloxy-2-(4-benzenesulfonyloxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo-[b]thiophene, hydrochloride 
• 84449-85-4 <6-<(methylsulfonyl)oxy>-2-<4-<(methylsulfonyl)oxy>phenyl>benzothien-3-yl><4-<2-(1-pyrrolidinyl)ethoxy>phenyl>methanone hydrochloride 
• 84449-83-2 6-benzoyloxy-2-(4-benzoyloxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, hydrochloride 
• 84541-36-6 [2-(4-methoxyphenyl)-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride 
• 84449-90-1 Raloxifen 
• 165742-76-7 [2-dimethylamino-6-methoxybenzothien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone 
• 166975-76-4 4-(2-(piperidin-1-yl)ethoxy)benzoyl chloride 

Relevant articles and documents

SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

3,5-Bis(benzylidene)-4-piperidones and related N-acyl analogs: A novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum

Drug resistance is a major challenge in antimalarial chemotherapy. In addition, a complete cure of malaria requires intervention at various stages in the development of the parasite within the host. There are only a few antimalarials that target the liver stage of the Plasmodium species which is an essential part of the life cycle of the malarial parasite. We report a series of antimalarial 3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs 1-5, a number of which exhibit potent in vitro growth-inhibiting properties towards drug-sensitive D6 and drug-resistant C235 strains of Plasmodium falciparum as well as inhibiting the liver stage development of the malarial life cycle. The compounds 2b (IC50: 165 ng/mL), 3b (IC50: 186 ng/mL), 5c (IC50: 159 ng/mL) and 5d (IC50: 93.5 ng/mL) emerged as lead molecules that inhibit liver stage Plasmodium berghei and are significantly more potent than chloroquine (IC50: >2000 ng/mL) and mefloquine (IC50: >2000 ng/mL) in this screen. All the compounds that showed potent inhibitory activity against the P. berghei liver stage were nontoxic to human HepG2 liver cells (IC50: >2000 ng/mL). The compounds 5a and 5b exhibit comparable metabolic stability as chloroquine and mefloquine in human plasma and the most potent compound 5d demonstrated suitable permeability characteristics using the MDCK monolayer. These results emphasize the value of 3,5-bis(benzylidene)-4-piperidones as novel antimalarials for further drug development.

Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds

The 3,5-bis(arylidene)-4-piperidones 1 contain the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore which is considered to interact at a complementary binding site in susceptible neoplasms. The hypothesis was formulated that the presence of an acyl group attached to the piperidyl nitrogen atom in series 1 may interact with an additional binding site thereby enhancing cytotoxic potencies. This concept led to the synthesis of various N-acyl-3,5-bis(arylidene)-4-piperidones 3-7 many of which displayed significant cytotoxicity towards a variety of cancer cell lines. A comparison of the potencies between the compounds in series 1 and the related nonquaternary analogues 3-6 revealed that in approximately half of the comparisons made, the N-acyl analogues had increased potencies.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R" represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Process for preparing benzoic acids

An improved process for the preparation of 4[(2-piperidin-1-yl)ethoxy]benzoic acid derivatives, comprising reacting a haloalkyl amine of formula (III) with a compound of formula (IV) in the presence of a hydrated inorganic base in an appropriate solvent.

Process for the synthesis of vinyl sulfoxides

The present invention is directed to a new process for the synthesis of vinyl sulfoxides, in particular diarylvinyl sulfoxides

Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals

The invention relates to intermediates and processes for producing benzothiophenes employing hydroxylamines.

Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals

The invention relates to novel intermediates of formula VI wherein R1and R2each are independently C1-C4alkyl, or R1and R2together with the nitrogen to which they are attached form a piperidinyl, pyrrolidinyl, methylpyrrolidinyl, dimethylpyrrolidinyl, morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino ring; n is 2 or 3; and Y1is p-toluenesulfonyl-O-, methylsulfonyl-O-, trifluoromethylsulfonyl-O-, 2,2,2-trifluoroethylsulfonyl-O-, or trifluoroacetyl-O-; or a salt or solvate thereof. and processes for producing benzothiophenes of formula II wherein R4and R5are each independently a hydroxy protecting group.

Process for the synthesis of benzo[b]thiophenes

The present invention is directed to new processes for the synthesis of 2-aryl benzo[b]thiophenes.

Process for the synthesis of benzo[b]thiophenes

The present invention is directed to a process for the synthesis of 2-arylbenzo[b]thiophenes.